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Abstract: BACKGROUND AND AIMS:  Mechanisms for the association between 
iron stores and risk factors for diabetes and cardiovascular disease, 
such as metabolic syndrome (MetS) and its components, are still not 
clear. We evaluated the associations between ferritin levels, MetS and 
its individual components, and potential role of confounding, in a meta-
analysis.  
 
METHODS: We searched articles in MEDLINE and EMBASE until February 
14th/2018. There were two approaches: Meta-analysis 1) of cross-sectional 
and longitudinal studies and 2) of only cross-sectional studies. Meta-
regressions were conducted to identify sources of heterogeneity in the 
associations of ferritin with MetS and its individual components.  
 
RESULTS: Information from 27studies (5 prospective) was systematically 
reviewed and 22 studies were meta-analysed. The pooled OR for MetS by 
increased ferritin was 1.78(95%CI: 1.60-1.97) in the meta-analysis 1, and 
1.70(95%CI: 1.49-1.95 in the meta-analysis 2. The pooled association was 
weaker in studies that adjusted for hepatic injury markers (meta-
regression coefficient (95% CI): -0.34(-0.60,-0.09) P= 0.008) and body 
mass index (BMI)(meta-regression coefficient(95% CI): -0.27(-0.53,-0.01) 
P = 0.039). Among MetS components, the pooled association with increased 
ferritin was strongest with high triglycerides [OR (95%CI): 1.96(1.65-
2.32)] and high glucose levels [OR 95%CI: 1.60(1.40-1.82)]. Higher cut-
off points used to define high ferritin concentrations were more strongly 
associated with high triglycerides [meta-regression coefficient (95% CI): 
0.22 (0.03, 0.041), P = 0.023].  
 
CONCLUSIONS: High triglycerides and glucose are the components more 
strongly associated with ferritin. Hepatic injury and BMI appear to 
influence the ferritin-MetS association, and a threshold effect of high 
ferritin concentration on the ferritin-high triglyceridesassociation was 
observed.  
 
 
 
 
 
Highlights 
 
- The associations between ferritin and metabolic syndrome (MetS) were meta-analysed. 
- Associations of ferritin with each MetS component were meta-analysed. 
- Ferritin was positively associated with MetS. 
- High triglycerides and glucose are the components more strongly linked to ferritin. 
- Hepatic injury and BMI appear to influence the ferritin-MetS association. 
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Abstract 
Background and aims:  Mechanisms for the association between iron stores and risk 
factors for diabetes and cardiovascular disease, such as metabolic syndrome  (MetS) and 
its components, are still not clear. We evaluated the associations between ferritin levels, 
MetS and its individual components, and potential role of confounding, in a meta-
analysis.  
 
Methods: We searched articles in MEDLINE and EMBASE until February 14
th
, 2018. 
There were two approaches: meta-analysis of 1) cross-sectional and longitudinal studies 
and 2) only cross-sectional studies. Meta-regressions were conducted to identify sources 
of heterogeneity in the associations of ferritin with MetS and its individual components.  
 
Results: Information from 27 studies (5 prospective) was systematically reviewed and 
22 studies were meta-analysed. The pooled OR for MetS by increased ferritin was 1.78  
(95%CI: 1.60-1.97) in the meta-analysis 1, and 1.70  (95%CI: 1.49-1.95) in the meta-
analysis 2. The pooled association was weaker in studies adjusted for hepatic injury 
markers (meta-regression coefficient  (95% CI): -0.34  (-0.60,-0.09) p= 0.008) and body 
mass index  (BMI)  (meta-regression coefficient  (95% CI): -0.27  (-0.53,-0.01) p= 
0.039). Among MetS components, the pooled association with increased ferritin was 
strongest with high triglycerides [OR  (95%CI): 1.96  (1.65-2.32)] and high glucose 
levels [OR 95%CI: 1.60  (1.40-1.82)]. Higher cut-off points used to define high ferritin 
concentrations were more strongly associated with high triglycerides [meta-regression 
coefficient  (95% CI): 0.22  (0.03, 0.041), p= 0.023].  
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Conclusions: High triglycerides and glucose are the components more strongly 
associated with ferritin. Hepatic injury and BMI appear to influence the ferritin-MetS 
association, and a threshold effect of high ferritin concentration on the ferritin-high 
triglycerides association was observed.  
 
Key words: iron, metabolic syndrome, insulin resistance 
 
 
Abbreviations 
MetS, metabolic syndrome; GGT, gamma-glutamyltranspeptidase/transferase; 
HDL-C, HDL cholesterol; HOMA-IR, homeostatic model assessment- insulin 
resistance; BMI, body mass index. 
 
Introduction 
Several systematic reviews and meta-analyses have described positive associations 
between increased iron stores, estimated as ferritin levels, and risk of type 2 diabetes 
mellitus  (T2D)  (1-3). Metabolic syndrome, a cluster of clinical and biochemical 
cardiovascular risk markers, known as MetS components, has been described as a risk 
factor for T2D and cardiovascular disease  (4). Although the relationship between serum 
ferritin and MetS has been evaluated in several studies, there is limited reviewed 
evidence for the association between ferritin and MetS. One meta-analysis reported an 
overall positive association but did not investigate associations of ferritin with 
individual components of the MetS (5). To date, it is not known whether serum ferritin 
is equally associated with each MetS abnormality or if there are components that would 
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explain most of the ferritin-MetS association.   Moreover, the role of important 
confounders such as BMI and hepatic function markers or threshold effects of ferritin 
levels in the overall association across published studies has not been evaluated 
previously. Several recent studies on the topic have been published between 2014 and 
2018, which have not been included in the previous meta-analysis, justifying an updated 
review to address the gaps mentioned above with more statistical power. Therefore, we 
conducted a systematic review and meta-analysis of ferritin, MetS, and its individual 
components, and explored sources of heterogeneity in the association.   
 
Materials and methods 
Search strategy  
Two authors  (MFSO and EEC) searched and selected articles from PubMed and 
EMBASE databases up to February 14,
 
2018. The following search terms were used: 
metabolic syndrome.mp. or metabolic syndrome X; ferritin or ferritin blood level or 
iron or body iron stores.mp. No restrictions regarding study design or article type were 
applied in the search, but unpublished reports were not considered. There were no 
disagreements about which studies to include, so advice from a third researcher was not 
needed. Only full texts and abstracts in English language were considered.  
Prevalence of MetS components were an additional outcome in this systematic 
review/meta-analysis. However, specific search terms of MetS components  (e.g. 
glucose, glycaemia, blood sugar levels, blood pressure) were not used since in a 
preliminary exploration, studies on iron markers and individual MetS components or 
MetS-related variables that did not include MetS as outcome were heterogeneous in 
terms of effect estimates and adjustments  (many of them unadjusted), which would 
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have made a quantitative analysis difficult. Studies on MetS as outcome were used to 
describe associations with MetS components as well, so the individual association 
between ferritin and each MetS component was evaluated in those studies providing this 
additional information.  
 
Study selection 
Eligibility criteria were studies that included participants from the general adult 
population with descriptions of associations, stratified by gender and age groups or 
adjusting for these covariates at a minimum. Study populations exclusively composed 
of children, pregnant women, obese individuals, or people with a specific diagnosis 
were not considered. Studies of animals or genetic polymorphisms and reports of in 
vitro experiments were also excluded. If two or more studies were based on the same 
population and same study design, the study with larger sample size was included. If the 
sample sizes were similar between studies of similar populations, the study with more 
robust adjustment was selected. If there were two studies with the same population but 
with different designs, both studies were selected, but they were analysed separately  
(see more detail below in data analysis).   
 
Data extraction and risk of bias  
The data extracted from the selected articles were name of the study, publication year, 
country, time of survey or baseline survey, age  (range or estimates), study design, 
sample size, percentage of male individuals, duration of follow-up, 
prevalence/incidence of MetS, MetS definition, ferritin levels, cut-off values for high 
ferritin, and covariates for adjustments. Risk of bias was evaluated according to 
modified criteria of the Newcastle-Ottawa scale modified by Orban and Huth (3) in 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
terms of representativeness, adjustment for confounders, description of exposure and 
outcome, and duration of follow-up  (if prospective design)  (Supplemental file 
Newcastle-Ottawa scale). The maximum and minimum scores were 7 and 0, 
respectively, and the higher the score the lower the likelihood of bias. Although 
representativeness is very complex to evaluate because a study can be representative of 
a specific location or group of people, we defined a study as representative if it was 
based on a national/regional health/nutrition survey, an epidemiological population-
based study, or if, for instance, random selection was reported in the recruitment of 
participants. 
 
Data synthesis and analysis 
Odds ratios  (ORs), hazard ratios  (HRs) or relative risks  (RRs), and their confidence 
intervals were extracted from the results described in the studies. Five studies describing 
mean ferritin levels reported by categories of MetS  (yes/no) were retained for the 
systematic review but excluded from the meta-analyses. For these studies we did not 
use any method to derive the ORs for the association between mean ferritin levels and 
MetS, since these methods assume normal distribution of the variable, and distribution 
of ferritin is frequently skewed across diverse general populations  (6, 7). In addition, a 
meta-analysis of mean differences for the four studies was not feasible owing to 
different effect estimates reported, in terms of normal mean, standardised mean, and 
mean of change in ferritin levels.  
 
We decided to conduct the meta-analysis on ferritin and MetS by using two approaches: 
meta-analysis of cross-sectional studies and prospective studies [meta-analysis 1] and 
meta-analysis of cross-sectional studies only [meta-analysis 2]. The main rationale 
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behind that decision was that there were few prospective studies, and it was necessary to 
ensure higher statistical power for meta-regression and sub-group analyses. The other 
reason was that some populations reported both cross-sectional and longitudinal 
associations, so it was relevant to determine the effect of both kinds of estimates on the 
pooled estimates and subgroup analyses. The meta-analysis on ferritin and MetS 
components did not require a similar approach since all of the studies describing 
associations between ferritin and MetS components were cross-sectional in design, with 
the only exception being Vari et al., who reported both cross-sectional and prospective 
associations (8). We used cross-sectional findings from the study by Vari et al. for this 
meta-analysis of the association between ferritin and MetS components.  
 
We pooled estimates from the studies by using an inverse-variance weighted random-
effects model. The I
2 
statistic was used to estimate heterogeneity in terms of the 
proportion of total variation in the estimates of meta-analysis explained by 
heterogeneity. For the meta-analysis 1 of cross-sectional and prospective studies, 
because most of the studies provided OR as effect estimate, hazard ratios, ORs and 
relative risks were assumed to approximate the same effect estimate of OR. Meta-
regression analyses were conducted to evaluate the potential factors accounting for 
heterogeneity in the associations between ferritin-MetS and between ferritin-Mets 
components throughout the selected studies. The factors were: study design  (cross-
sectional or prospective), type of effect estimate  (OR, HR, relative risk), geographic 
region  (Asia, Europe, America), adjustment for BMI  (yes/no), adjustment for CRP  
(yes/no), adjustment for any inflammatory marker  (yes/no), adjustment for hepatic 
function markers  (yes/no), sample size  (<500 or ≥500), sample size  (<1000 or ≥1000), 
ferritin assay  (chemiluminescence QLA, radiometry, RIA; inmunoturbidimetry, TIA; 
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others), average ferritin levels reported, and cut-off points reported for the highest 
category of ferritin levels. For these latter two factors, we calculated quartiles specific 
of sex and menopausal status or whole population as reported in each study selected. In 
meta-regression analysis, if the meta-regression coefficient is negative, it indicates an 
inverse association between the potential factor of heterogeneity and the association 
evaluated. For instance, if the characteristic of adjusting for inflammation markers  (yes 
v. no) across the studies shows a negative meta-regression coefficient in relation to the 
pooled ferritin-MetS association, this indicates that adjusting for inflammation markers 
attenuates the pooled association.   Sub-group analyses in terms of stratified ferritin-
MetS or ferritin-MetS components associations by factors of heterogeneity were 
performed for those factors that were found significantly associated in the meta-
regression analyses. Publication bias was evaluated by using Begg’s and Egger’s test as 
well and visualisation of funnel plots. A p value < 0.05 was considered statistically 
significant All analyses were processed using STATA 14.0 software  (Statistics/Data 
Analysis, Stata Corporation, 4905 Lakeway Drive, College Station, TX 77845, USA, 
800-STATA-PC). 
 
Results 
Studies with the same population and decisions made 
Information on these cases  (9-23)] is provided in the Supplemental file.  
 
Studies selected  
Figure 1 summarises the process of identifying and selecting the studies. We identified 
27 studies that described the association between ferritin and MetS of which 18 were 
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included in the meta-analyses and systematic review and five only contributed to the 
systematic review  (Table 1). Among the studies selected, there were 9 studies for the 
meta-analysis on the association between ferritin and the five MetS components. Three 
studies were prospective only, and two reported cross-sectional and prospective 
evaluations. The rest of the studies  (81%) were cross-sectional analyses. 
 
MetS definitions, geographic location, and types of source 
Information on MetS definitions used  (24-27) and populations’ characteristics is 
described in the Supplemental file and shown in Table 1. 
 
Adjustments 
Two studies exclusively involved post-menopausal women  (28), another, only women  
(both pre and post-menopausal)  (10), and four, only men  (15, 16, 29, 30). Information 
on adjustment variables used in the studies is shown in Table 1. Since basic adjustments 
for age and sex were the inclusion criteria for this systematic review, all of the studies 
showed either adjustments or stratified results for age and sex.Eleven studies reported 
adjustment for BMI  (9, 10, 18-20, 29, 31-35), 11 for CRP levels as marker of sub-
clinical/clinical inflammation,  (9, 14, 16-20, 23, 31, 33, 34, 36), and 6 reported 
adjustments for both covariates  (18-20, 31, 33, 34). Four from those with no covariate 
of CRP, adjusted for white blood cell count  (15, 37, 38) or other inflammatory markers 
such as fibrinogen levels  (35). Thirteen studies reported adjustments for hepatic 
function in terms of transaminase levels  (9, 10, 16, 19, 20, 23, 28, 30, 32, 33, 37, 38)or 
non-alcoholic fatty liver disease  (39), two, for family history of chronic diseases  (32, 
34), and five,for the surrogate of insulin resistance HOMA-IR (10, 15, 16, 23, 37), of 
which four did not adjust for BMI  (15, 16, 23, 37). With the exception of eight studies  
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(8, 17, 36, 37, 39-42), all others adjusted for alcohol intake. Two articles included 
education level as covariate  (9, 40), out of which one additionally adjusted for variables 
such as urban or rural residence and income  (40). However, this latter study did not 
adjust for other factors.  
 
Average ferritin concentrations and cut-off values defining high ferritin 
Median/mean values of ferritin levels and cut-offs of ferritin defining high 
concentration reported in the studies selected are shown in Supplemental Tables 1 and 
2, respectively. The values are grouped by sex/menopausal status/sex-specific tertiles 
and quartiles. All of the studies described cut-offs for high ferritin lower than suggested 
reference values  (>200 µg/L in women, >300 µg/L in men)  (5), with the exception of 
Kilani et al.  (326 µg/L in men)  (19, 20) and Tang et al.  (459.9 (cross-sectional study) 
and 426.6 µg/L  (prospective study) in men)  (29).  
 
Risk of bias 
Supplemental tables 3 and 4 describe our evaluation of risk of bias in cross-sectional 
and prospective studies, respectively. The median score for risk of bias, which is 
inversely related to opportunity of bias, was 4. Two cross-sectional studies, i.e. Sun et 
al.  (34) and Jehn et al. (31), reached the maximum possible score of 7 for lower risk of 
bias  (Supplemental Table 3). Of note, many studies with very robust adjustments did 
not obtain high scores, presumably because one of the assessment criteria was the 
simultaneous adjustment for BMI and inflammatory markers. Failure to report 
coefficients of variation in ferritin measurements was another common reason for not 
obtaining higher scores  (Supplemental tables 3and 4). 
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Ferritin and metabolic syndrome: Results of the meta-analysis and meta-
regression  
Information from 78,851 individuals was obtained when cross-sectional and prospective 
studies were analysed together  (meta-analysis 1; 19 studies). The pooled OR for MetS 
by high levels of ferritin  (vs. lowest levels) was 1.78  (95% CI: 1.60–1.97) 
[heterogeneity p< 0.001; I
2
57.2%]  (Fig. 2A). When prospective effect estimates were 
replaced by cross-sectional effect estimates in the case of articles or populations 
providing both associations (meta-analysis 2; 16 studies; 82,332 participants), the 
pooled OR for MetS for the highest levels of ferritin  (vs. lowest levels) was 1.70  (95% 
CI: 1.49–1.95) [heterogeneity p< 0.001; I2 79.2%]  (Fig. 2B). The overall ORs for MetS 
components by high levels of ferritin  (vs. lowest levels)  (meta-analysis 3) are shown in 
Fig. 3. High triglycerides and glucose were the components more strongly associated 
with high levels of serum ferritin [high fasting glucose 1.60  (1.40–1.82) heterogeneity 
p< 0.001; I
2
 77.8%]; high triglycerides 1.96  (1.65–2.32) heterogeneity p< 0.001; I2  
82.8%]; low HDL-C 1.47  (1.30–1.66) [heterogeneity p< 0.001; I2 60.7%]; and high 
blood pressure 1.13  (1.04–1.23) [heterogeneity p= 0.074; I2 34.7%]. Supplemental Fig. 
1-5 show detailed forest plots for the association between serum ferritin and MetS 
components. 
 
The meta-regression analysis with study characteristics as independent variables is 
shown in Table 2. In meta-analysis 1, the pooled estimates for association between 
ferritin and MetS was stronger when RIA  (reference category) was the laboratory 
method for ferritin measurement than with other methods  (Table 2) [meta-regression 
coefficient  (95% CI): -0.09  (-0.018,-0.002), p= 0.045]. Pooled ORs for MetS by sub-
groups of laboratory method are shown in Supplemental Fig. 7. No others potential 
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factors of heterogeneity were identified for the meta-analysis 1. However, in the meta-
analysis of only cross-sectional studies, adjusting for BMI and adjusting for hepatic 
markers  (yes vs. no) attenuated the association between ferritin and MetS[BMI meta-
regression coefficient  (95% CI): -0.27 (-0.53,-0.01) p= 0.039; hepatic markers meta-
regression coefficient  (95% CI): -0.34 (-0.60,-0.09) p= 0.008 ]  (Table 2). 
Supplemental Fig. 8 and 9 provide stratified odds ratios by groups of studies adjusting 
and not adjusting for BMI and hepatic markers, respectively. As in meta-analysis 1, 
ferritin assay was also found as source of heterogeneity for ferritin –MetS association 
although with marginal statistical significance  (p=0.077)  (Table 2).   
 
The meta-regression analysis also showed that adjusting for CRP strengthened the 
association of ferritin with high triglycerides and high glucose (Supplemental Table 5)  
(Supplemental Fig. 10 and 11). On the other, hand the ferritin-high blood pressure 
association was attenuated in studies adjusting for BMI (Supplemental Table 5)  
(Supplemental Fig. 12). In studies with lower risk of bias  (risk of bias score > median 
score), high ferritin was less strongly associated with high triglycerides, WC, and blood 
pressure  (Meta-regression p< 0.038)  (Supplemental Table 5)  (Supplemental figures 
13, 14 and 15). In addition, higher cut-off points used to define high ferritin 
concentrations were more strongly associated with high triglycerides [meta-regression 
coefficient  (95% CI): 0.22 (0.03, 0.041), p= 0.023]  (Table 3)  (Supplemental Fig.  16). 
 
Findings from studies for the systematic review but not included in the meta-
analysis 
All these articles described significantly higher levels of ferritin in cases with MetS. 
More details on these associations are provided in the Supplemental file.  
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Sensitivity analyses 
Information on sensitivity analyses is provided in the Supplemental file. 
 
Publication bias 
The funnel plot for the ferritin-MetS association was asymmetrical with most of the 
studies located on the top left of the diagram  (Supplemental Fig. 17). However, 
according to Begg’s and Egger’s tests, there was no evidence for publication bias  
(p=0.713 and p=0.299, respectively). 
 
 
Discussion 
The meta-analysis suggested a positive overall association between ferritin and MetS. 
The meta-regression for the ferritin-MetS association identified weaker associations 
when the studies adjusted for BMI and hepatic function. With regard to the overall 
association between ferritin and MetS components, stronger positive associations were 
observed with triglycerides and fasting glucose in comparison with other components. 
Moreover, subgroup and meta-regression analyses also showed that in studies with 
higher cut-off points defining upper categories of ferritin levels, the association with 
high triglycerides was stronger.  
 
Ferritin and MetS: comparison with previous systematic review/meta-analyses 
In the present meta-analysis, we describe a similar pooled overall positive OR for 
ferritin and MetS to that recently reported by Abril-Ulloa et al.  (5), [ (1.76  (95% CI: 
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1.57–1.97) vs. 1.73  (1.54–1.95), respectively]. However, the present meta-analysis had 
several differences from the previous one. First, the inclusion criteria of the present 
systematic review/meta-analysis required adjustment for at least age and sex. Second, 
there were four additional prospective studies  (18, 20, 23, 29) and six additional cross-
sectional studies  (19, 28-30, 36, 41). Third, we explored adjustment for BMI and 
hepatic function markers and threshold effects of ferritin values across study 
populations as sources of influence on the overall ferritin-MetS association. Lastly, 
associations between ferritin and individual MetS components were also described to 
identify whether there were any differences.  
 
 
Factors influencing the ferritin-MetS association 
Neither Abril-Ulloa et al.  (5) nor we found that study design, kind of effect estimate, 
geographic area, and study size influenced the ferritin-MetS association. The trend 
identified but not discussed by Abril-Ulloa et al. of a stronger association in studies 
which used immunoradiometric assays for ferritin measurement than in those which 
used other assays  (p= 0.091)  (5), was statistically significant  (p= 0.045) in the present 
meta-analysis. In contrast to the study of Abril-Ulloa et al.  (5), in this updated meta-
analysis, adjustment for CRP levels was not identified as a source of heterogeneity for 
the ferritin-MetS association. A possible explanation is that Abril-Ulloa et al.  (5) 
included some articles reporting unadjusted associations. We found that adjusting for 
CRP strengthened the pooled association with high triglycerides and glucose, similar to 
the effect observed by Abril-Ulloa et al. for the ferritin-MetS association which was 
unexpected. CRP levels are considered a confounder since inflammation increases 
ferritin levels because ferritin is also a phase-acute reactant  (43), and cardiometabolic 
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risk has been widely associated with inflammatory response  (44). One would expect 
effect estimates for ferritin-MetS or ferritin-triglycerides association to be attenuated in 
CRP-adjusted models rather than the pattern observed. 
 
There were no differences in average ferritin levels or cut-off values for high ferritin by 
category of laboratory assay  (data not shown). Therefore, the influence of the assay in 
the heterogeneity of ferritin-MetS association cannot be attributed to the threshold effect 
of the values of ferritin measurement. Since the meta-analysis by Abril-Ulloa et al. also 
described a similar finding  (5), possible explanations should be considered. However, 
there are no major differences in the accuracy of the current methods for measuring 
serum ferritin to explain the heterogeneity observed. The heterogeneity of the ferritin-
MetS association by ferritin assay could also be a chance finding.  
 
Adjusting for BMI and hepatic function markers  (mostly transaminases) attenuated the 
pooled ferritin-MetS association across the studies evaluated. BMI is a well-known 
anthropometric predictor of cardiometabolic diseases  (CMD) (45) and is positively 
correlated with iron stores  (46). Obesity, estimated as high BMI, is also associated with 
both iron deficiency and increased ferritin. It appears that adipocytokines stimulate 
synthesis and secretion of the hormone hepcidin which inhibits intestinal iron 
absorption and release by tissues, causing iron deficiency  (47)]. Similarly, low-grade 
inflammation in obesity can lead to increasing ferritin levels even in the context of iron 
deficiency  (47)]. Iron excess in obesity could be explained by mechanisms of IR 
affecting iron homeostasis  (48)]. Thus, adjusting for BMI allows investigation of 
whether any ferritin-MetS association exists independently of obesity. More than half of 
the studies included did not adjust for BMI, and their authors did not give a rationale for 
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not using BMI as covariate. Meanwhile, because ferritin is mostly produced in the liver, 
damage to hepatic cells positively influences circulating ferritin levels because it gets 
released into the bloodstream  (49)]. Similarly, hepatic function markers have been 
associated with cardiovascular risk factors  (50)]. In future research, the role of 
adjustment for BMI, hepatic function markers for evaluating confounding, effect 
modification, and potential underlying mechanisms should be considered.  
 
Ferritin and MetS: pooled association vs. inconsistencies 
Although the meta-analysis identified a pooled positive significant association between 
ferritin and MetS, there were several studies describing non-significant association. For 
instance, Zelberg et al. did not find a significant association in an Israeli population 
(39), and Kilani et al., in men or women (20). Interestingly, along with the latter study, 
the studies by Jehn et al.  (31), Kim et al.  (33), Lee et al.  (9), and Shi et al. (40) failed 
to find an independent association in men, a demographic subgroup with higher iron 
status. There were no consistent associations by sex or menopausal status, with some 
studies reporting associations in women but not in men and others reporting the reverse. 
 
Ferritin and MetS components  
Stronger associations were observed between ferritin and high triglycerides or high 
fasting glucose than with other components of the MetS. There is growing experimental 
evidence that metabolism of glucose and of iron are interrelated and in a bidirectional 
way  (43, 51). For instance, in murine models, starvation-induced gluconeogenesis 
promoted iron hepatic deposition, and high hepatic stores of iron caused 
hyperinsulinemia by decreasing insulin extraction or affecting insulin signalling  (43). 
This latter effect of iron could promote dyslipidaemia owing to high triglycerides. The 
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association between ferritin and triglycerides could also be two-way based on findings 
in animals, where high-fat diets stimulated intrahepatic deposition of iron  (43). In light 
of the above, high levels of glucose and triglycerides appear to be the components that 
make the largest contribution to a positive association between ferritin and MetS. The 
finding that the association between ferritin and MetS remained significant after 
adjustment for IR  (HOMA-IR) in the four studies that included this adjustment is 
interesting. In two of these studies that showed unadjusted and adjusted associations, a 
marked attenuation of the association was observed only in one  (OR  (95%CI) 3.45  
(3.03–3.92) to 1.99  (1.70–2.33))  (15). The above points imply that association between 
ferritin and MetS is not entirely explained by the associations with hyperinsulinemia 
and that there are alternative and still unknown, underlying mechanisms.  
 
The subgroup analysis of the association of ferritin and MetS components suggested the 
presence of heterogeneity between the studies. For instance, the high blood pressure-
ferritin association was weaker when the studies adjusted for BMI as was found for the 
ferritin-MetSassociation. On the other hand, there were other sources of influence 
specific to individual associations between ferritin and other MetS components. The 
association between ferritin and high triglyceride was significantly influenced by the 
cut-off value for high ferritin reported in the studies. Meanwhile, studies with greater 
risk of bias can overestimate specific associations between ferritin and increased WC, 
triglycerides, and blood pressure on the basis of low representativeness and/or non-
adjustment for BMI. It is unclear why these factors were not similarly found as sources 
of influence in the ferritin-MetS association. The above discrepancy suggests that each 
component of MetS may have specific patterns of association with ferritin regardless of 
the pattern with the risk cluster.  
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Ferritin, MetS and its components: role of non-alcoholic hepatic steatosis  (NASH) 
and fatty liver? 
Our findings on stronger association of ferritin with high glucose and triglycerides, 
components highly related to insulin resistance, plus the influence of BMI on the 
ferritin-MetS association may involve liver alterations. In fact, insulin resistance and 
ferritin have been described as major determinants of non-alcoholic fatty liver disease in 
apparently healthy obese patients  (52). Serum ferritin concentrations were also 
significantly higher in NASH patients than in the patients with simple steatosis  (53). In 
this latter study, the serum ferritin level was associated with insulin resistance, with an 
area under the ROC curve of 0.732 for distinguishing NASH from simple steatosis  (p= 
0.005; 95% CI, 0.596-0.856). Thus, high ferritin levels, in addition to be a marker of 
MetS, could constitute a marker of fatty liver in obese people that usually have high 
triglyceride and glucose levels. In this context, and to close the circle, serum ferritin 
levels have been described to be associated with vascular damage in patients with non-
alcoholic fatty liver disease  (54). 
 
Strengths and limitations 
To the best of our knowledge, this study appears to be the first meta-analysis on ferritin, 
MetS, and its individual components. In addition, the investigation of the influence of 
adjustments for body mass and hepatic function and of threshold effects of ferritin on 
the ferritin-MetS association across the studies represents another novel contribution. 
On the other hand, some findings from the subgroup and meta-regression analysis were 
not consistent throughout the sensitivity analysis. This implies limitations in statistical 
power or chance findings arising from multiple testing. Given the different assumptions 
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in the calculation of effect estimates from prospective and cross-sectional studies, 
analysing them together might not be appropriate, although no heterogeneity by effect 
estimate or study design was detected in the subgroup meta-regression analysis. 
However, this potential limitation was balanced by conducting an additional meta-
analysis specific to cross-sectional studies with all the studies reporting associations as 
ORs.  
 
In conclusion, the meta-analysis suggests a significant overall positive association 
between ferritin and MetS. Hepatic injury, BMI, and type of ferritin assay appear to 
influence the ferritin-MetS association. It also appears to exist a threshold effect of high 
ferritin concentration on the associations with high triglycerides. High triglycerides and 
glucose are the MetS components most strongly associated with ferritin levels and could 
explain most of the association with the risk cluster known as MetS.  
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LEGENDS TO FIGURES 
Figure 1. Flow chart for the selection of eligible studies included in the systematic 
review/meta-analysis of the association between ferritin and metabolic syndrome. 
Figure 2. Forest plots describing the association  (odds ratio 95 % confidence 
interval) between ferritin and metabolic syndrome in:  (A) cross-sectional and 
longitudinal studies [Meta-analysis 1] and  (B) only cross-sectional studies [Meta-
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analysis 2]. Studies are stratified by sex, menopausal status or presented both sexes 
depending on the way the association was reported in each article. Diamonds are pooled 
estimates from inverse variance weighted effects random models.  
 
Figure 3. Overall pooled odds ratios  (95 % confidence interval) for association 
between high levels of ferritin  (vs. lowest levels) and each MetS component. 
Detailed forest plots for these associations are shown in supplemental material. 
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Yoon et 
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follow-up) 
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Park et 
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health 
checkup 
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al.,2013 
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sectional Taiwan 
population 
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 (women) 
for Asia 
Pacific 
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chronic diseases  
Li et al. , 
2013 (14) 
Cross-
sectional 
China/China 
population 
CHNS /2009 ≥18 46.6 8441 19.9% (Men), 
25.4% 
 (women) 
NCEP ATP-III 
for Asia 
Americans 
No Yes Nationality, 
alcohol intake and 
smoking 
Kilani et 
al., 2014 
(19) 
Cross-
sectional 
Switzerland/ 
Population 
from 
Lausanne 
The 
CohorteLausa
nnoise/ 
2003-2006 
35-75 47.2 5498 29.4% (Men) 
8.3% 
(premenopausal 
women) and 
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(postmenopausal 
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supplement and 
altered hepatic 
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women) 
Ledesma 
et al., 2015 
(30) 
Cross-
sectional 
Spain/ 
workers 
from a 
factory in 
Zaragoza 
The Aragon 
Workers’ 
Health 
Study/2009-
2019 
19-65 100 3386 27.1 Harmonized 
definition 
No No History of blood 
donations, alcohol 
intake and 
transaminases 
Seo et al., 
2015 (28) 
Cross-
sectional 
Korea/ 
Users of a 
health 
promotion 
NP/2008-2010 >40 0 280 25~% NCEP ATP-III  
(BMI used 
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transaminases and 
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center in 
Seoul 
circumference) (E2, total 
testosterone, FSH, 
and TSH) 
Tang et 
al., 2015 
(29) 
Cross-
sectional/Pr
ospective 
(4 years 
follow-up) 
China/ Men 
from 
Guangxi 
Fangchenggan
g Area Males 
Health and 
Examination 
Survey/2009-
2013 
17-88 100 2417 Prevalence :12.7 
% 
Incidence: 9.42% 
NCEP ATP-III 
for Asia 
Americans 
Yes No  Physical activity, 
family history of 
chronic diseases, 
alcohol intake and 
smoking status 
Kilani et Prospective Switzerland/ The 35-75 42.8 3271 22.6% (Men), and NCEP ATP-III Yes Yes Alcohol intake, 
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Table 1. Characteristics of the studies included in the systematic review and meta-analysis and in the systematic review only of the association between ferritin 
and metabolic syndrome  (seven pages table) 
STUDIES INCLUDED IN THE SYSTEMATIC REVIEW AND META-ANALYSIS 
Authors, 
year  (Ref) 
Study Location/ 
Universe  
Study-Survey 
/Year of 
survey 
Age 
range  
 
(years)* 
Male  
(%) 
n Prevalence of 
metabolic 
syndrome 
 
MetS 
definition 
 
Adjustments 
         BMI CRP Other 
adjustments 
al., 2015 
(20) 
(5.5 years 
follow-up 
Population 
from 
Lausanne 
CohorteLausa
nnoise/ 
2003-2006 
16.5 % 
 (women) 
smoking,  iron 
supplement and 
altered hepatic 
markers 
Suarez-
Ortegon et 
al., 2016 
(35) 
Cross-
sectional 
Croatia/ 
population 
from the 
villages Vis 
and Komiza 
Dalmatians 
Research 
Programme/ 
2003-2004 
18-93 39.1 725 50.7% (Men) 
33.8% 
(premenopausal 
women) and 
88.6% 
(postmenopausal 
Harmonized 
definition 
Yes No Fibrinogen levels,  
smoking,and 
alcohol 
consumption 
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Table 1. Characteristics of the studies included in the systematic review and meta-analysis and in the systematic review only of the association between ferritin 
and metabolic syndrome  (seven pages table) 
STUDIES INCLUDED IN THE SYSTEMATIC REVIEW AND META-ANALYSIS 
Authors, 
year  (Ref) 
Study Location/ 
Universe  
Study-Survey 
/Year of 
survey 
Age 
range  
 
(years)* 
Male  
(%) 
n Prevalence of 
metabolic 
syndrome 
 
MetS 
definition 
 
Adjustments 
         BMI CRP Other 
adjustments 
women) 
Cho et al., 
2017 (38) 
Cross-
sectional 
Korea/ 
Korea 
population  
KNHANES 
/2010-2012 
58.7±0.
4 
0 2734 Not provided for 
the whole 
population. MetS 
prevalence was 
40.3%-64.8% 
from the lowest 
till highest 
quartile of ferritin 
NCEP ATP-III No No Smoking, alcohol 
consumption, 
regular exercise, 
and leukocyte 
count 
Chen et Cross- China/ Population- 25-75 47.5 2786 42% (Men), and IDF No No Serum creatinine, 
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STUDIES INCLUDED IN THE SYSTEMATIC REVIEW AND META-ANALYSIS 
Authors, 
year  (Ref) 
Study Location/ 
Universe  
Study-Survey 
/Year of 
survey 
Age 
range  
 
(years)* 
Male  
(%) 
n Prevalence of 
metabolic 
syndrome 
 
MetS 
definition 
 
Adjustments 
         BMI CRP Other 
adjustments 
al., 2017 
(37) 
sectional Population 
from Pinggu 
district, 
Beijing  
based study / 
2012-2013  
45% 
 (women) 
ALT, 
Neutrophils/Lymp
hocytes ratio, 
frequency of pork 
consumption and 
HOMA-IR 
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STUDIES INCLUDED ONLY IN THE SYSTEMATIC REVIEW 
Authors Study Location/ 
Universe  
Study-Survey 
/Year of 
survey 
Age 
range  
 (years) 
Male  
(%) 
n Prevalence of 
metabolic 
syndrome 
 
MetS 
definition 
 
Adjustments 
         BMI CR
P 
Others 
adjustments 
Martinelli 
et al.,2012 
(36) 
Cross-
sectional 
Italy/ Val 
Borbera 
population  
Val 
Borbera/NP 
>18 44.3 1391 21.9% Harmonized 
definition 
No Yes C282Y HFE 
mutation, 
haemoglobin, uric 
acid, and 
creatinine 
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43 
44 
45 
46 
47 
48 
49 
Hamalain
en et 
al.,2012 
(17) 
Cross-
sectional 
Finland/Mid
dle –aged 
subjects 
from 
Pieksamaki 
who were 
born in 
1942,1947,1
952,1957 or 
1962 
NP/2003-2004 52.1 ± 
6.2 years 
(men) 
and 52.1 
± 6.2 
years  
(women) 
44.5 766 53% (men), 40% 
 (women) 
NCEP ATP-
III 
No Yes Smoking, alcohol 
intake and 
physical activity 
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Hamalain
en et 
al.,2014 
(18) 
Prospective 
(6.5 years 
follow-up) 
Finland/Mid
dle –aged 
subjects 
from 
Pieksamaki 
who were 
born in 
1942,1947,1
952,1957 or 
1962 
NP/1998-2004 45.3 ± 
6.2 years 
(men) 
and 45.1 
± 6.5 
years  
(women) 
41.8 691 Incidence :18% Harmonized 
definition 
Yes Yes Smoking, alcohol 
intake and 
physical activity 
Iwanaga 
et al., 2011 
(41) 
Cross-
sectional 
Japan/in 
individuals 
from a 
worksite 
lifestyle 
intervention 
study 
NP/2007 41.2 ± 
10.4 
years 
42.7 685 13.6  (men), 
1.7  (women) 
Japanese 
criteria 
No No None 
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Padwal et 
al., 2015 
(42) 
Cross-
sectional 
India/ 
Patients 
from 
Outpatient 
department 
University 
Medical 
College, 
Pune 
2013 ≥30 50% 90 Not apply. Age-
sex matched case-
control study  (50 
cases with MetS) 
NCEP ATP-
III 
No No None 
* * Or mean  (SD) of age if age range not provided. ** This study used BMI instead of waist circumference as surrogate for central obesity. Ref, reference. NP, Not 
provided. 
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Table 2. Effect of diverse studies’ characteristics  on the pooled ferritin-MetS association  
 Prospective and cross-sectional 
studies 
 (Meta-analysis 1) 
Cross-sectional studies only 
 (Meta-analysis 2) 
 Number 
of 
studies* 
Meta-regression 
coefficient  
(95%CI) 
P 
value 
Number 
of 
studies* 
Meta-regression 
coefficient  
(95%CI) 
P value 
Study design  
 (Cross-sectional v. 
Prospective) 
19 (36) -0.11 (-0.35,0.11) 0.320 18 (33) ** ** 
Measure of association  
 (Odds ratio/ Hazard ratio/ 
Relative risk) 
19 (36) 0.10 (-0.19,0.39) 0.497 18 (33) ** ** 
Region  (Asia/ 
Europe/America) 
19 (36) -0.02 (-0.19,0.14) 0.782 18 (33) -0.07 (-0.29,0.14) 0.484 
Adjusted for BMI  
 (Yesv. No) 
19 (36) -0.14 (-0.35,0.05) 0.154 18 (33) -0.27 (-0.53,-0.01) 0.039 
Adjusted for CRP 
 (Yesv. No) 
19 (36) 0.14 (-0.06,0.34) 0.178 18 (33) -0.08 (-0.37,0.21) 0.578 
Adjusted for at least one 
inflammatory marker 
 (Yesv. No) 
19 (36) 0.08 (-0.12,0.29) 0.394 18 (33) -0.06 (-0.34,0.21) 0.631 
Adjusted for at least  
one hepatic function 
marker (Yesv. No) 
19 (36) -0.16 (-0.36,0.04) 0.121 18 (33) -0.34 (-0.60,-0.09) 0.008 
Ferritin assay 
 (RIA/ QLA/ TIA/Other) 
19 (36) -0.09 (-0.18,-0.002) 0.045 18 (33) -0.11 (-0.23,0.01) 0.077 
Sample size≥1000 19 (36) 0.07 (-0.05,0.29) 0.528 18 (33) -0.05 (-0.38,0.28) 0.748 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Risk of bias 
  (score ≥ median score) 
 (Yesv. No) 
19 (36) -0.09 (-0.30,0.11) 0.375 18 (33) 0.06 (-0.21,0.33) 0.653 
Sex/menopausal-specific 
quartiles  (1-2-3-4) of 
mean/median ferritin levels 
19 (36) -0.01 (-0.11,0.08) 0.742 18 (33) -0.09 (-0.21,0.03) 0.144 
Sex/menopausal-specific 
quartiles  (1-2-3-4) of cut-
off points reported for 
highest category of ferritin 
levels  
18 (33) 0.07 (-0.03,0.17) 0.187 17 (30) 0.004 (-0.14,0.15) 0.955 
* The first number describes number of studies, and second number  (in parenthesis) means sex/menopausal status 
groups from each study. 
**These characteristics do not apply since all studies in the meta-analysis 2 were cross-sectional and reported the 
same kind of effect estimate: Odds ratio  (95% confidence interval).  
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Dear Drs von Eckardstein and Dallinga-Thie, 
 
Thank you for your e-mail of April 8
th
. We appreciate all your comments and suggestions as 
well as those from the reviewers of our manuscript. 
A point-by-point response to the associate editor’s and reviewers’ comments is enclosed. All 
suggestions have been addressed. Modifications throughout the manuscript are in red font. We 
would be pleased to provide additional information or to further modify the text.  
The current version of article has 4408 words (introduction, methods, results and discussion) due 
to the addition of a new and pertinent paragraph in discussion section suggested by the reviewer 
#1.  There are 200 words more in the legends of tables and figures. We believe that additional 
reduction of words count would imply to loose clarity in methods and discussion. We hope this 
little excess of words can be accepted taking into account that the article is not only a meta-
analysis but also a systematic review. 
We look forward to hearing from you. Thank you very much for your attention to our 
manuscript. 
 
Sincerely yours, 
José Manuel Fernández-Real and Milton Fabian Suárez-Ortegón 
 
The authors are grateful for the reviewer' comments which have contributed to clarify 
the message of our paper and to improve the quality of our submission.  
The specific comments are addressed below:  
*Point-by-Point Response
  
 
 
 
 
Reviewers' comments 
 
Reviewer #1 
Milton Fabian Suárez-Ortegón et al. have performed a meta-analysis and systematic 
review on the association between ferritin and metabolic syndrome and its components. 
The main conclusion is that there is a clear association between ferritin and MS 
particularly with triglycerides and glucose components. 
 
The role of ferritin in the context of metabolic diseases remains uncertain and clinicians 
could be mislead by high ferritin concentrations in these patients. Therefore, this study is 
welcome because contributes to establish the association of ferritin levels and metabolic 
diseases. 
 
The study has been very well conducted. The quality controls applied to studies included 
in the analyses are robust. The number of studies included is large enough. Therefore the 
results are highly reliable. 
R/ Many thanks for this opinion. 
At the end the authors show a strong association between TG, G and BMI that probably 
determine high ferritin levels independently of metabolic syndrome definition. It is 
known that these three factors are associated to fatty liver that is associated to high 
ferritin levels, even in the absence of liver damage (high transaminases). I think that in 
the discussion such association should be better addressed and the role of fatty liver and 
NASH as high ferritin levels determinants, must be taken into account at least in the 
discussion. Are high ferritin levels a marker of MS or a marker of fatty liver in obese 
people that usually have high TG and glucose levels? 
 
R/ We fully agree with this comment. We greatly acknowledge this idea. We have added a 
paragraph at the end of discussion section, as follows: 
“Ferritin, MetS and its components: role of non-alcoholic hepatic steatosis (NASH) and 
fatty liver? 
 
Our findings on stronger association of ferritin levels with high glucose and triglycerides, 
components highly related to insulin resistance, plus the influence of BMI on the ferritin-
MetS association may involve liver alterations. In fact, insulin resistance and ferritin have 
been described as major determinants of non-alcoholic fatty liver disease in apparently 
healthy obese patients (52). Serum ferritin concentrations were also significantly higher in 
NASH patients than in the patients with simple steatosis (53). In this latter study, the serum 
ferritin level was associated with insulin resistance, with an area under the ROC curve of 
0.732 for distinguishing NASH from simple steatosis (P = 0.005; 95% CI, 0.596-0.856). 
Thus, high ferritin levels, in addition to be a marker of MetS, could constitute a marker of 
fatty liver in obese people that usually have high triglyceride and glucose levels. In this 
context, and to close the circle, serum ferritin levels have been described to be associated 
with vascular damage in patients with non-alcoholic fatty liver disease (54).” 
 
From my point of view the data in supplementary material are more clinically relevant 
that the tables in the paper. I suggest including at least a figure showing the data from 
the Forest plots between ferritin and the MS components, probably showing only the 
overall results for each variable, while tables 2 and 3 could be send to supplementary 
material.  
 
R/ We agree with this comment of the reviewer. We have created a new figure, 
Figure 3, which show overall pooled estimates for associations between high 
ferritin (v. low ferritin) and each MetS component. Supplemental figures 1-5, show 
the detailed forest plots for the above associations. We sent the Table 3 to the 
supplemental material, and this is now the new Supplemental Table 5. We kept 
Table 2 in the main manuscript since the Journal enables until 5 tables/figures. The 
current manuscript has two tables and three figures. Here we present the 
modifications in results section: 
 
Figure 3. Overall pooled odds ratios (95 % confidence interval) for association between high 
levels of ferritin (vs. lowest levels) and each MetS component. Detailed forest plots for these 
associations are shown in supplemental material. 
 
“The overall ORs for MetS components by high levels of ferritin (vs. lowest levels) (meta-
analysis 3) are shown in Figure 3. High triglycerides and glucose were the components more 
strongly associated with high levels of serum ferritin [high fasting glucose 1.60 (1.40–1.82) 
heterogeneity P < 0.001; I
2
 77.8%]; high triglycerides 1.96 (1.65–2.32) heterogeneity P < 
0.001; I
2
 82.8%]; low HDL-C 1.47 (1.30–1.66) [heterogeneity P < 0.001; I260.7%]; and high 
blood pressure 1.13 (1.04–1.23) [heterogeneity P = 0.074; I234.7%]. Supplemental figures 1-
5 show detailed forest plots for the association between serum ferritin and MetS 
components.” 
 
 
“The meta-regression analysis also showed that adjusting for CRP strengthened the 
association of ferritin with high triglycerides and high glucose (Supplemental Table 5) 
(Supplemental figures 10 and 11). On the other, hand the ferritin-high blood pressure 
association was attenuated in studies adjusting for BMI (Supplemental Table 5)……” 
 
 
Reviewer #2 
The paper by Suarez-Ortegon et al reports a systematic review and meta-analysis on the 
potential association of circulating ferritin levels with the MetS. The authors meta-
analyzed this relationship by 2 approaches: meta-analysis of cross-sectional/longitudinal 
studies and only cross-sectional studies. Moreover, a subgroup analysis considering the 
association of ferritin with MetS components was also conducted. 
 
The paper deals with a relevant issue of significant clinical relevance. 
The paper appears consequential in its sections and is clearly readable. The Authors 
conclude that high TG and glucose are the components of the MetS more associated 
with ferritin levels. Moreover, liver disease and BMI strongly influenced the ferritin-MetS 
association. 
 
The statistical approach appears correct and solid in reaching sound conclusions. Overall, 
more than 78,000 individuals were included in the analysis. The Discussion section is of 
appropriate length and properly discusses the data obtained within the literature 
context. 
R/ Many thanks for this opinion. 
Specific and minor comments: 
 
Highlights 
The first 2 sentences may be re-written using 1) an impersonal wording (not "we...") and 
2) making the second statement independent from the first one. 
R/ The two first highlights have been corrected as the reviewer suggested: 
“- The associations between ferritin and metabolic syndrome (MetS) were meta-analysed. 
- Associations of ferritin with each MetS component were meta-analysed.” 
 Introduction, line 6: 
at least here at the beginning add the word "mellitus" after…type 2 diabetes …. 
R/ Added as the reviewers suggested: 
“Several systematic reviews and meta-analyses have described positive associations between 
increased iron stores, estimated as ferritin levels, and risk of type 2 diabetes mellitus (T2D).” 
 
Methods, Data synthesis and analysis, second page of this section, line 16: 
"quimioluminiscencia" appears to be the correct word in Spanish. Use 
"chemiluminescence" here, in English. 
R/ Corrected as the reviewers suggested:  
“ferritin assay (chemiluminescence QLA, radiometry, RIA; inmunoturbidimetry, TIA; 
others),…..” 
 
 
 
 
Reviewer #3 
The associations of ferritin levels, metabolic syndrome and the individual components of 
metabolic syndrome have been investigated in a meta-analysis of 22 studies. It has been 
concluded that high triglycerides and glucose are the metabolic syndrome components 
that are more strongly associated with ferritin. It was also found that hepatic dysfunction 
and BMI influence the ferritin-metabolic syndrome association. A threshold effect of high 
ferritin concentration on the ferritin-high triglycerides association was also found. This is 
an interesting report that extends a number of previous reports of an association of 
ferritin levels with metabolic syndrome. 
Overall, this is a valuable addition to previous studies of the relationship between ferritin 
and the metabolic syndrome. 
R/ Many thanks for these opinions. 
Some of the grammar could be improved. 
R/ Grammar and style have been revised by a professional academic proof-reading 
service. 
Otherwise, there are no issues requiring attention. 
 
 
Editorial Office comments 
 
-Atherosclerosis applies formatting guidelines to all accepted papers, with the aim of 
improving their readability. 
Manuscripts that do not conform to the format guidelines of the Atherosclerosis Journal 
will be returned to the authors for reformatting. 
When revising your manuscript, please follow carefully the recommendations of our 
Atherosclerosis Style Guide to be downloaded from the following link 
(http://cdn.elsevier.com/promis_misc/Atherosclerosis_style_guide_checklist.docx). 
 
-  Make sure to apply the formatting requirements to all figures and tables where 
necessary (e.g. style of p values, gene and protein nomenclature). 
R/ Checked as requested. 
- Make sure to use uniform lettering and sizing of your original artwork, including letters 
to indicate panels, throughout all figures.  
R/ Checked as requested. 
- Make sure to submit high resolution versions of each figure. 
R/ High resolution figures have been uploaded. 
Statement of Originality 
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elsewhere while under consideration. This article has not been published elsewhere, 
and, if accepted, it will not be published elsewhere—either in similar form or verbatim—
without permission of the editors.  
All authors are responsible for reported research, and have participated in the concept 
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